Received: 16 July 2022
Accepted: 28 July 2022
First Online: 26 August 2022
: The study was approved by the Internal Review Board of the University of L’Aquila with protocol number (02/2017); an informed consent was signed by all participants.
: Not applicable.
: FP has received speaker honoraria from Novartis, unrelated to the submitted work. SS reports consultant, advisory board, or speaker fees from Abbott, Allergan, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Eli Lilly, Medscape, Medtronic, Novartis, Starmed, Teva, and Uriach., all unrelated to the submitted work. RO reports personal fees from Novartis, Teva, and Eli Lilly, and non-financial support from Novartis and Teva, all unrelated to the submitted work.Other authors declare that they have no competing interests.